Human leukocyte antigen (HLA) typing is performed for checking the compatibility of patients and donors for cord blood or bone marrow transplants. HLA are proteins in our body. Human immune system uses these kinds of markers to find out which cells belong in your body and which cells are alien.
HLA typing checks for the exceptional group of HLA antigens for an individual. HLA-class I and class II antigens identification is done by molecular diagnostic procedures which is based upon DNA. HLA typing uses these advanced DNA innovations and provides more healthy and accurate testing results that are dependable in identifying different HLA genes.
A perfect match between a donor and patient is necessary for HLA markers and a successful transplant. HLA matching boosts the growth and progress of new healthy blood cells which is called engraftment and reduces the risk of any complication after the transplant which is called graft-versus-host disease.
COVID-19 scenario analysis:
Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicines supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are short of these drugs. Owing to the demand for vaccine and treatment drugs for COVID-19, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future.
Owing to such factors, COVID 19 is expected to have a significant impact on HLA typing for transplant market.
Top impacting factors: Market Scenario Analysis, Trends, Drivers and Impact Analysis
The increasing funding for target research activities from public and private sectors, increase in the number of cases for infectious diseases, increasing number of transplant procedures, and upgrades in technology for transplant diagnostics are the major factors boosting the growth of HLA typing transplant market. Also, there has been a rise in demand for solid organ transplants. These transplants are essential for heart, lung, liver and kidney disorder. Molecular assays techniques are also been upgraded in the recent years helping the growth of HLA transplants in the market. Additionally, increase in adoption of cross-matching and Chimerism testing during before and after transplantation. There is also a shift occurring between non-molecular serological assays to gene-based HLA profiling. Awareness amongst the people is also increasing and people are more inclined towards organ donation and transplantation across emerging countries. All these factors are resulting in the growth of the HLA typing for transplant market.
On the other side, high costs for molecular HLA typing for transplant tests limit the adoption. We also observe huge gap between supply and demand for organ donations which is effecting patient waiting time.
New product launches to flourish the market:
On June 14, 2018, Caredx facilitated HLA labs to real time PCR.
On May 4, 2018, CareDx and Illumina entered into an agreement which provides CareDx access to global distribution rights for TruSight HLA.
In February 2017, Immucor launched its MIA FORA NGS FLEX HLA typing assay which provides a comprehensive coverage of up to 11 genes.
Surge in usage in hospital applications:
Rapid modernization and diagnostic laboratories automation along with growing number of research & development activities being outsourced by pharmaceutical & biotechnology companies to independent laboratories, and the growing number of organ transplantation procedures are creating surge of HLA typing in hospitals.
Majority of tests and transplants are conducted in hospitals because of the availability of highly skilled professionals and advanced medical equipment. Number of patients requiring transplants and being admitted is increasing in hospitals which will further keep on increasing. Academic and research institutes are using of HLA tests on a large scale for various experiments. The hospitals segment is expected to hold the highest share of global HLA typing transplant diagnostics services market.
Key benefits of the report:
- This study presents the analytical depiction of the global HLA Typing for Transplant industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global HLA Typing for Transplant market share.
- The current market is quantitatively analyzed to highlight the global HLA Typing for Transplant market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed global HLA Typing for Transplant market analysis based on competitive intensity and how the competition will take shape in coming years.
Questions answered in the HLA Typing for Transplant Market research report:
- What are the leading market players active in the HLA Typing for Transplant market?
- What the current trends will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities in the market?
- What are the projections for the future that would help in taking further strategic steps?
HLA Typing for Transplant Market Report Highlights
By End User
Key Market Players
Omixon Inc., Bio Reference Laboratories, Bio-Rad Laboratories Inc., Histogenetics LLC, TBG Diagnostics Ltd., Immucor Inc., Hologic Inc., Becton Dickinson and Company, Abbott Laboratories Ltd., CareDX Inc.